Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, Zhang X, Pan H, Niu Z, Qiu M, Qin Y, Fang W, Ye F, Li N, Liu T, Liu A, Zhang X, Hu C, Zhang J, Cui J, Lin X, Wang S, Zhang J, Lin T, Qu X, Yuan X, Gong J, Li J, Gao W, Gai L, Wang Y, Yuan D, Li Z, Shen L. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial,Lancet,Lancet. 2025 Jun 7;405(10494):2049-2060. doi: 10.1016/S0140-6736(25)00860-8. Epub 2025 May 31.

Li J, Tao M, Liu L, Liu C, Ma M, Liu D, Zhang P, Zhang M, Xue R, Gong J, Zhang C, Zhang X, Shen L, Qi C. Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer,Br J Cancer,Br J Cancer. 2025 Jun;132(12):1167-1176. doi: 10.1038/s41416-025-03015-3. Epub 2025 Apr 17.

Liu D, Gong J, Li J, Qi C, Niu Z, Liu B, Peng Z, Luo S, Wang X, Wang Y, Zhao R, Chen L, Deng T, Li Z, Chen L, Fang M, Yang H, Lu L, Zhang Y, Kang F, Xu T, Zhang X, Shen L. Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study,Signal Transduct Target Ther,Signal Transduct Target Ther. 2025 Mar 19;10(1):104. doi: 10.1038/s41392-025-02195-x.

Qi C, Shen L, Andre T, Chung HC, Cannon TL, Garralda E, Italiano A, Rieke DT, Liu T, Burcoveanu DI, Neu N, Mussi CE, Xu RH, Hong DS, Drilon A, Berlin J. Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer,Eur J Cancer,Eur J Cancer. 2025 May 2;220:115338. doi: 10.1016/j.ejca.2025.115338. Epub 2025 Mar 4.

Ma M, Liu C, Jiang L, Liu D, Zhang P, Tao M, Zhang M, Gong J, Peng Z, Zhang X, Li J, Zheng C, Deng M, Shen L, Qi C. Exploring the therapeutic efficacy difference in claudin18.2-targeted cell therapy revealed by single-cell sequencing,iScience,iScience. 2025 Jan 7;28(2):111768. doi: 10.1016/j.isci.2025.111768. eCollection 2025 Feb 21.

Qi C, Liu D, Liu C, Wei X, Ma M, Lu X, Tao M, Zhang C, Wang X, He T, Li J, Dai F, Ding Y, Shen L. Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells,J Immunother Cancer,J Immunother Cancer. 2024 Oct 4;12(10):e009960. doi: 10.1136/jitc-2024-009960.

Jiang L, You F, Wu H, Qi C, Xiang S, Zhang P, Meng H, Wang M, Huang J, Li Y, Chen D, An G, Yang N, Zhang B, Shen L, Yang L. B7-H3-Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors,Cancer Res,Cancer Res. 2024 Dec 2;84(23):4066-4080. doi: 10.1158/0008-5472.CAN-24-0195.

Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Lu Z, Lu M, Cao Y, Yuan J, Wang Y, Wang Z, Xue R, Peng X, Wang Y, Yuan D, Li J, Zhang X, Shen L. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results,Nat Med,Nat Med. 2024 Aug;30(8):2224-2234. doi: 10.1038/s41591-024-03037-z. Epub 2024 Jun 3.

Qi C, Zhang P, Liu C, Zhang J, Zhou J, Yuan J, Liu D, Zhang M, Gong J, Wang X, Li J, Zhang X, Li N, Peng X, Liu Z, Yuan D, Baffa R, Wang Y, Shen L. Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials,J Clin Oncol,J Clin Oncol. 2024 Jul 20;42(21):2565-2577. doi: 10.1200/JCO.23.02314. Epub 2024 May 24.

Qi C, Guo R, Chen Y, Li C, Liu C, Zhang M, Zhang C, Zhang X, Hou X, Chen B, Jia B, Yang Z, Shen L, Zhu H. (68)Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients,J Nucl Med,J Nucl Med. 2024 Jun 3;65(6):856-863. doi: 10.2967/jnumed.123.267110.

Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K. Claudin 18.2 as a novel therapeutic target,Nat Rev Clin Oncol,Nat Rev Clin Oncol. 2024 May;21(5):354-369. doi: 10.1038/s41571-024-00874-2. Epub 2024 Mar 19.

Qi C, Chong X, Zhou T, Ma M, Gong J, Zhang M, Li J, Xiao J, Peng X, Liu Z, Li Z, Shen L, Zhang X. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study,Chin J Cancer Res,Chin J Cancer Res. 2024 Feb 29;36(1):78-89. doi: 10.21147/j.issn.1000-9604.2024.01.08.

Qi C, Xie T, Zhou J, Wang X, Gong J, Zhang X, Li J, Yuan J, Liu C, Shen L. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer,J Hematol Oncol,J Hematol Oncol. 2023 Sep 9;16(1):102. doi: 10.1186/s13045-023-01491-9.

Wang S, Qi C, Ding J, Li D, Zhang M, Ji C, Jiang F, Teng F, Yu J, Qian X, Wang F, Shen L, Gao J, Yang Z, Zhang C, Zhu H. First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection,Eur J Nucl Med Mol Imaging,Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2802-2817. doi: 10.1007/s00259-023-06234-z. Epub 2023 Apr 26.

Qi C, Zhou T, Bai Y, Chen H, Yuan J, Zhao F, Liu C, Ma M, Bei T, Chen S, Zhao X, Chen C, Shen L. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment,Int J Cancer,Int J Cancer. 2023 Dec 1;153(11):1916-1927. doi: 10.1002/ijc.34522. Epub 2023 Apr 23.

Wang Z, Zhang Q, Qi C, Bai Y, Zhao F, Chen H, Li Z, Wang X, Chen M, Gong J, Peng Z, Zhang X, Cai J, Chen S, Zhao X, Shen L, Li J. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer,J Immunother Cancer,J Immunother Cancer. 2022 Jun;10(6):e004703. doi: 10.1136/jitc-2022-004703.

Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, Zhang X, Lu Z, Lu M, Yuan J, Wang Z, Wang Y, Peng X, Gao H, Liu Z, Wang H, Yuan D, Xiao J, Ma H, Wang W, Li Z, Shen L. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results,Nat Med,Nat Med. 2022 Jun;28(6):1189-1198. doi: 10.1038/s41591-022-01800-8. Epub 2022 May 9.

Zhang M, Qi C, Wang Z, Chen H, Zhao X, Zhang X, Zhou Y, Gao C, Bai Y, Jia S, Ji J. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy,J Mol Med (Berl),J Mol Med (Berl). 2021 Sep;99(9):1311-1321. doi: 10.1007/s00109-021-02093-z. Epub 2021 May 31.